stockmarketproxy
/
CRSPNasdaq SEC EDGAR

CRISPR Therapeutics AG

Biological Products, (No Diagnostic Substances)·ZUG·FY end 12/31·CIK 1674416
OverviewFinancialsCompensationGovernanceInsidersFilings

Financials

5-year history · USD
MetricFY 2025FY 2024FY 2023FY 2022FY 2021Trend
Revenue$3.5M$37.3M$371.2M$1.2M$915.0M
Gross Profit——————
Operating Income-$664.6M-$466.6M-$222.5M-$673.2M$373.5M
Net Income-$581.6M-$366.3M-$153.6M-$650.2M$377.7M
Operating CF-$345.0M-$142.8M-$260.4M-$495.7M$539.0M
Capex$914.0K$1.9M$9.5M$37.2M$81.7M
Free Cash Flow-$345.9M-$144.7M-$269.8M-$532.9M$457.3M
Buybacks——————
Dividends——————
Gross Margin——————
Operating Margin-18933.6%-1250.4%-60.0%-56190.4%40.8%
Net Margin-16569.8%-981.5%-41.4%-54271.7%41.3%
FCF Margin-9855.5%-387.7%-72.7%-44484.9%50.0%
R&D / Revenue8114.1%859.3%104.3%38534.6%47.9%
Effective Tax-0.6%-1.0%-1.9%0.0%0.5%
Debt / Equity——————
Buybacks / FCF——————

Peer comparison

Biological Products, (No Diagnostic Substances) · 5 peers
CEO Pay Ratio
CRSP
26:1
EXEL
81:1
GILD
119:1
BIIB
113:1
PCVX
48:1
IBRX
69:1
CEO total comp
CRSP
—
EXEL
$33M
GILD
$28M
BIIB
$24M
PCVX
$14M
IBRX
$13M
Net Margin
CRSP
-16569.8%
EXEL
33.7%
GILD
28.9%
BIIB
13.1%
PCVX
—
IBRX
-310.2%